



Slavery and Human Trafficking Statement

25 May 2023

Introduction from the Chief Financial Officer

Slavery and human trafficking remain an unfortunate reality of societies across the world. At Quotient Sciences Limited ("Quotient") we are proud to confirm our commitment to maintaining ethical and transparent employment practices which are at the very heart of our corporate values. The Modern Slavery Act 2015 brings into law policies that have been the foundations of Quotient's fair employment policies since the Company's inception in 1990.

Quotient is committed to ensuring that all of its suppliers and subcontractors are also fully compliant with Quotient's own internal policies and the law to ensure that we are doing all we can to combat slavery and human trafficking around the world. Therefore, Quotient strives to perpetuate throughout its supply chain a corporate culture free from slavery, human trafficking and any other unfair, unethical or illegal employment practices.

Organisation's Structure

Quotient are a provider of early phase clinical research, drug manufacturing, formulation development and data analysis services in the pharmaceutical development sector with a head office in the United Kingdom. Throughout our group we have over 1100 employees worldwide and operate throughout Europe and North America.

Quotient has an annual turnover in excess of £36 million.

Our Supply Chains

Our supply chains include providers of:

- clinical trials and drug manufacturing equipment including but not limited to medical apparatus, peripherals and other chemistry wares;
- specialised, industry specific equipment and technologies; and
- clinical trial specific human sample analysis.

Our Policies on Slavery and Human Trafficking

We are committed to ensuring that there is no modern slavery or human trafficking in our supply chains or in any part of our business. Our anti-slavery ethos reflects our commitment to acting ethically and with integrity in all our business relationships and to implementing and enforcing effective systems and controls to ensure slavery and human trafficking is not taking place anywhere in out supply chains.

Due Diligence Processes for Slavery and Human Trafficking

As part of our initiative to identify and mitigate risk we have in place systems to:

identify and assess potential risk areas in our supply chains;

- mitigate the risk of slavery and human trafficking occurring in our supply chains;
- monitor potential risk areas in our supply chains; and
- we encourage reporting of concerns and whistle blowers.

Supplier Adherence to Our Values

Quotient has zero tolerance to slavery and human trafficking. We expect all those in our supply chain comply with our values and encourage a culture of transparency on such matters.

In 2021 we launched a Supplier Code of Ethics and Conduct which makes explicit our expectation that our suppliers adhere to the highest standards of business ethics, including zero tolerance of modern slavery, that employment should be freely chosen and child labour will not be used.

The Supplier Code of Ethics and Conduct is supported by our Sustainable Procurement Policy which further details our expectations in this area.

Copies of both documents can be found on the relevant section of our website: <u>Suppliers</u> (quotientsciences.com).

We have a number of departments involved in ensuring that our suppliers meet our standards, including:

- Legal Affairs;
- · Human Resources; and
- Quality Assurance.

Our Effectiveness in Combating Slavery and Human Trafficking

We use the following key performance indicators to measure how effective we have been to ensure that slavery and human trafficking is not taking place in any part of our business or supply chains:

- all suppliers are validated against Quotient's quality management system;
- key suppliers are audited and profiled as required; and
- the Company uses a sophisticated payroll system.

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes our slavery and human trafficking statement for the financial year to 31 December 2022.

Des Glass

CFO

Quotient Sciences Limited